<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36D29AB3-EDC8-47C6-A6D8-DA041424DF34"><gtr:id>36D29AB3-EDC8-47C6-A6D8-DA041424DF34</gtr:id><gtr:name>Cellectricon</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/583FFC26-8AD4-46BA-8DB4-3BF480EAF532"><gtr:id>583FFC26-8AD4-46BA-8DB4-3BF480EAF532</gtr:id><gtr:name>One North East, Newcastle</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F62D14B6-E917-49C9-ABB4-5AEF64C8900E"><gtr:id>F62D14B6-E917-49C9-ABB4-5AEF64C8900E</gtr:id><gtr:name>Tokai Pharmaceuticals Inc</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Northern Institute for Cancer Research</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36D29AB3-EDC8-47C6-A6D8-DA041424DF34"><gtr:id>36D29AB3-EDC8-47C6-A6D8-DA041424DF34</gtr:id><gtr:name>Cellectricon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/583FFC26-8AD4-46BA-8DB4-3BF480EAF532"><gtr:id>583FFC26-8AD4-46BA-8DB4-3BF480EAF532</gtr:id><gtr:name>One North East, Newcastle</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F62D14B6-E917-49C9-ABB4-5AEF64C8900E"><gtr:id>F62D14B6-E917-49C9-ABB4-5AEF64C8900E</gtr:id><gtr:name>Tokai Pharmaceuticals Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/584EC7A6-0F03-413E-A444-AD288D6E29DC"><gtr:id>584EC7A6-0F03-413E-A444-AD288D6E29DC</gtr:id><gtr:firstName>Craig</gtr:firstName><gtr:otherNames>Nigel</gtr:otherNames><gtr:surname>Robson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601123"><gtr:id>885F0FB3-63F9-4D69-88B8-3446B555E488</gtr:id><gtr:title>Ubiquitin-mediated regulation of androgen receptor function: a potential therapeutic target in prostate cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601123</gtr:grantReference><gtr:abstractText>More than 10,000 men die annually in the UK from prostate cancer. The standard therapy for prostate cancer aims to block the androgen receptor signalling pathway by removing its activating hormone, androgen from the circulation and/or blocking androgen action. However, most cancers become resistant to treatment and become refractory to hormone manipulation. The outlook for these patients is poor. 
A detailed functional analysis of the proteins that contribute towards signalling through the androgen receptor pathway should identify alternative, novel targets for treatment of this disease.
In this project we will focus on studying the enzymes that modify the function of proteins by directly attaching or removing a small protein called ubiquitin. Addition of ubiquitin, termed ubiquitination, or removal of ubiquitin from proteins, termed deubiquitination, are important events in regulating many of the functions of the androgen receptor. 
Activation of the androgen receptor is critical to all the stages of prostate cancer, including later stages of the disease when standard treatments are ineffective. We aim to identify those proteins implicated in androgen receptor ubiquitination and deubiquitination and further determine the importance of these proteins in androgen receptor action. Our ultimate hope is that we can disrupt the enzymatic action of these proteins using small molecule chemical inhibitors. In this way we may be able to provide alternative treatments for those prostate cancer patients who no longer respond to standard treatments.
Consistent with our research Institute?s policy we will fully engage the wider public with our research findings through press communications, organised open days, school visits and attendance at charity events.</gtr:abstractText><gtr:technicalSummary>Androgen ablation is widely used in prostate cancer (CaP) therapy. However, most tumours become resistant to treatment but still retain a functional androgen receptor (AR) signalling pathway. 

Proteasomal turnover and transcriptional activity of the AR are subject to regulatory control by ubiquitination. Characterising the proteins that regulate ubiquitination of the AR may provide alternative targets for treatment of advanced CaP.

This study will determine the regulatory influence of ubiquitination on transcriptional activity and proteasomal degradation of the AR and further investigate the potential of using small molecule inhibitors to disrupt ubiquitin-mediated AR signalling in CaP. The aim is to identify novel protein within the AR protein transcriptional complex as alternative targets for therapeutic intervention in CaP.

This project will 
(1) Investigate the degradation of wild type and mutant AR in CaP cell lines in response to ligand modulation and proteasomal inhibitors

(2) Apply small molecule inhibitors that modulate AR phosphorylation or interfere with AR chaperone binding to investigate AR degradation and function

(3) Determine the sites of ubiquitination of the AR both in vitro and in vivo

(4) Identify deubiquitinating enzymes linked to AR transcriptional activity

(5) Evaluate protein expression and genetic alterations of selected gene products that modulate AR ubiquitination in clinical material to determine their relevance to the initiation and progression of CaP</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>350153</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Characterisation of a Novel Series of Small Molecule Androgen</gtr:description><gtr:id>4A50061B-19A2-4C38-A416-67EEF3E7A172</gtr:id><gtr:impact>This is a joint funded project between AZ and the MRC (to commence in Jan 2009 for 3 years). this will further strengthen interactions between my research group and AZ.</gtr:impact><gtr:outcomeId>48B53AE430B-1</gtr:outcomeId><gtr:partnerContribution>This is a joint funded project between AZ and the MRC (to commence in Jan 2009 for 3 years). this will further strengthen interactions between my research group and AZ.</gtr:partnerContribution><gtr:piContribution>This is a joint funded project between AZ and the MRC (to commence in Jan 2009 for 3 years). this will further strengthen interactions between my research group and AZ.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellectricon</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>High throughput siRNA library screening</gtr:description><gtr:id>3CF15131-7835-49A8-BB6D-D97A256D2E21</gtr:id><gtr:impact>Methodology gained from G0601123 will be applied in a high throughput screening format developed by Cellectricon</gtr:impact><gtr:outcomeId>32011A15A8F-1</gtr:outcomeId><gtr:partnerContribution>Methodology gained from G0601123 will be applied in a high throughput screening format developed by Cellectricon</gtr:partnerContribution><gtr:piContribution>Technology input and experience in prostate biology, including small-medium scale siRNA library screens.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>One North East, Newcastle</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NEPAF Collaboration</gtr:description><gtr:id>EA3CE4F5-75AF-469E-B2AB-B6ED525E4862</gtr:id><gtr:impact>NEPAF - North East Proteome Analysis Facility - has conducted some proteomics analysis for our group on this project for which they received payment. However, we are currently in negotiation with NEPAF to seek a commitment from them to provide financial support to develop a particular area of related research. At this point no funding has been secured.</gtr:impact><gtr:outcomeId>804A572D387-1</gtr:outcomeId><gtr:partnerContribution>Interegation of post-translational modification of the androgen receptor</gtr:partnerContribution><gtr:piContribution>Provision of unique reagents and expertise</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Development of a Ubiquitin Proteome Consortium</gtr:description><gtr:id>2B7A2F4C-FD71-4932-8971-6E780AE73D5E</gtr:id><gtr:impact>Ongoing discussion for financial support from Cancer Research UK. 
Identification of a novel deubiquitinase enzyme in prostate cancer cells.</gtr:impact><gtr:outcomeId>F49SDhUY1xr-1</gtr:outcomeId><gtr:partnerContribution>Specialist expertise in deubiquitinase assays</gtr:partnerContribution><gtr:piContribution>Reagent distribution, expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tokai Pharmaceuticals Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Tokai - anti-androgen therapy</gtr:description><gtr:id>2FD5B1B6-4129-4402-8B49-D5D7549E52EF</gtr:id><gtr:impact>Funded research in our laboratories to explore Tokai small molecules and to develop more potent small molecules that are beneficial in prostate cancer therapy</gtr:impact><gtr:outcomeId>56c46c48ef0784.27155502-1</gtr:outcomeId><gtr:partnerContribution>Provide small molecules for study in collaboration</gtr:partnerContribution><gtr:piContribution>Identified a deubiquitinase enzyme that is targetted by small molecule anti-androgen produced by Tokai</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Haendler Collaboration</gtr:description><gtr:id>29179361-76A2-4388-B523-95ECE4048A40</gtr:id><gtr:impact>Speeded up reseach programme</gtr:impact><gtr:outcomeId>B29A738BF6B-1</gtr:outcomeId><gtr:partnerContribution>Expert advice, provision of unique reagents</gtr:partnerContribution><gtr:piContribution>Exchange of unique reagents</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Division of Cell Biology</gtr:department><gtr:description>Ubiquitin Probes</gtr:description><gtr:id>79C5A38B-6F48-4B3A-AAE1-76E00DEE07FE</gtr:id><gtr:impact>publication
Chemistry
Molecular and Cell Biology</gtr:impact><gtr:outcomeId>SxkXM6dXcn2-1</gtr:outcomeId><gtr:partnerContribution>Synthesis of selected probes and antibody generation</gtr:partnerContribution><gtr:piContribution>Biological assay development and application</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cancer fund raising event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A572DB98-45C5-4464-AC10-964D210FC0E6</gtr:id><gtr:impact>Short talk on research highlights to date

Positive interaction with patient groups and stimulated their further interest to lobby government , MPs and specific prostate charities to devote more monies to this research area</gtr:impact><gtr:outcomeId>cqEpJ7uBTmC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Charity Fun Run</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D1508CE1-A77C-4544-A84C-184B12CCD0EA</gtr:id><gtr:impact>Short presentation of research to large audience (primarily female) of between 3000-6000 audience. Including interviews with local press and local radio.

Informal discussions with smaller groups of cancer sufferers/ survivors and patient representative group</gtr:impact><gtr:outcomeId>57D08B04414</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute Open Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1570E178-9264-44EE-943B-05A0D152E25C</gtr:id><gtr:impact>3-4 hour planned session, 2-3 times yearly, on a Saturday morning. Visits of approx 100 members of public. Short presentations and demonstrations of equipment by 4-6 research groups. Closing with 1 to 1 discussions over coffee/tea.

Contact maintained with several individual members of public</gtr:impact><gtr:outcomeId>1E6BD3447F6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Movember Fundraising - Prostate Cancer Awareness</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B7E81D1E-4F16-4968-BCBA-9002688DB315</gtr:id><gtr:impact>Approx 100 workers from Proctor and Gamble PLC made aware of prostate cancer (briefly mentioned other cancers) risk factors and nature of research programme to combat disease

2012 gave two talks to different groups and this stimulated a series of talks for 2013 and additional events related to fundraising and public awareness of prostate cancer</gtr:impact><gtr:outcomeId>EG9xpsxntp1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.uk.pg.com   http://uk.movember.com/</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit - Gaughan</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2F899D45-99F5-4851-AEC0-8C3AD1B2F972</gtr:id><gtr:impact>Gaughan as RC UK Fellow had meetings with local teachers to discuss workshops for school students. Presentations from Gaughan to teachers. Outreach being extended to presentations to school children.

Continuing programme to encourage students from underachieving schools to engage with science</gtr:impact><gtr:outcomeId>9CFB58901B0</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Dr William Edmund Harker Foundation</gtr:department><gtr:description>Sir William Edmond Harker Foundation</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:id>44C54269-E8B8-4F44-A9F2-80FD62D752A0</gtr:id><gtr:outcomeId>sox2EbSpGvw0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newcastle University + Cancer Research UK PhD Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>45B0AB5B-1369-45FA-B2DF-0A34CEC13BAD</gtr:id><gtr:outcomeId>Z4NY36JPS9v1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>198000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PCC Project grant</gtr:description><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>B0868A40-5B3D-4D74-8A23-9BB5F228EC5F</gtr:id><gtr:outcomeId>Tx6kH8CkpNQ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newcastle University + Cancer Research UK PhD Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:id>48CDDA13-74B7-4B6A-96E4-E1A4C06EFE2E</gtr:id><gtr:outcomeId>Z4NY36JPS9v0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Collaboration with Industry</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>73204F53-8A9A-4854-82A3-E7E8E5D16689</gtr:id><gtr:outcomeId>C11CCE1DDBB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI Biomarkers and Imaging Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>721122DF-F0B7-44DC-A555-6E00D7C6845B</gtr:id><gtr:outcomeId>owPdiYiMotU</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Purified recombinant forms of the AR mutated at specific amino acid sites</gtr:description><gtr:id>20496077-989D-431A-9AF4-AF2DDAB76E81</gtr:id><gtr:impact>In vitro assays of ubiquitination and AR protein activity</gtr:impact><gtr:outcomeId>0BA1094BE64</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>AR REC MUT</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Purified forms of 4 E3 ligases</gtr:description><gtr:id>4FE527E9-E609-4923-B8F7-263257911DD9</gtr:id><gtr:impact>High throughput in vitro ubiquitination assays</gtr:impact><gtr:outcomeId>71C5ABE10CA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>REC E3 LIGASE</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Integrated DUB siRNA expressing plasmid, for inducible knockdown in prostate cancer cells</gtr:description><gtr:id>1DB22D76-2B90-4549-9580-D73D5D2E3FE4</gtr:id><gtr:impact>Temporal control of DUB expression to evaluate importance in androgen receptor transcriptional control</gtr:impact><gtr:outcomeId>D4A28B618A1</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DUB KD LNCaP</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>siRNA screen developed and applied including assay development to monitor expression of changes to androgen regulated genes</gtr:description><gtr:id>4BD6BCBB-11DB-4864-B224-CC5136DFFD42</gtr:id><gtr:impact>High throughput screening enabled with reproducible assay that is cost effective and simple</gtr:impact><gtr:outcomeId>N1jVFCz3vcZ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>siRNA screening</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5C61E783-401F-4D06-A2DA-ECE421501688</gtr:id><gtr:title>Deubiquitinating enzymes as oncotargets.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c4027559bb1164360ce012e50d0bbf"><gtr:id>d6c4027559bb1164360ce012e50d0bbf</gtr:id><gtr:otherNames>McClurg UL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56c46468a95704.24816057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4547AF95-9586-4A9C-BFE9-810626BD60F7</gtr:id><gtr:title>Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c4027559bb1164360ce012e50d0bbf"><gtr:id>d6c4027559bb1164360ce012e50d0bbf</gtr:id><gtr:otherNames>McClurg UL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>58bff099c37524.58555959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A180810-055F-4DB6-A93A-D770A05869BB</gtr:id><gtr:title>Regulation of the androgen receptor by SET9-mediated methylation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d33bf1e67bab06e27a4ff2aa938b3921"><gtr:id>d33bf1e67bab06e27a4ff2aa938b3921</gtr:id><gtr:otherNames>Gaughan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>YacpmmJgGiH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50C3DA72-DD46-47CC-B57B-6B669B4219FB</gtr:id><gtr:title>Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e027e1ed23e63230037a8d8990f8df"><gtr:id>18e027e1ed23e63230037a8d8990f8df</gtr:id><gtr:otherNames>O'Neill D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5629f5021804b5.09699195</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B641C6D-83E0-4B2F-8597-2C0B8DC4345E</gtr:id><gtr:title>FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac494d475208dcbe97475e9b9d7b64fd"><gtr:id>ac494d475208dcbe97475e9b9d7b64fd</gtr:id><gtr:otherNames>Brooke GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>ZS8AQg2HfSj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F4BC1B0-BC98-450E-B1C2-78F7D406142A</gtr:id><gtr:title>Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c4027559bb1164360ce012e50d0bbf"><gtr:id>d6c4027559bb1164360ce012e50d0bbf</gtr:id><gtr:otherNames>McClurg UL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>54510943597725.86342947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C0E5859-5CAB-447A-B526-9E2C171EE693</gtr:id><gtr:title>Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5911ce2f2ce71b2e98bcf7b340bfcce8"><gtr:id>5911ce2f2ce71b2e98bcf7b340bfcce8</gtr:id><gtr:otherNames>Burska UL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_12954_24_24056413</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601123</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>